Free Trial
→ Get Your Bank Account “Fed Invasion” Ready with THESE 4 Simple Steps (From Weiss Ratings) (Ad) Buy PHAT Stock  Free PHAT Stock Alerts

Phathom Pharmaceuticals (PHAT) Financials

Phathom Pharmaceuticals logo
$2.58 -0.18 (-6.52%)
Closing price 05/5/2025 04:00 PM Eastern
Extended Trading
$2.56 -0.02 (-0.78%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Phathom Pharmaceuticals

Annual Income Statements for Phathom Pharmaceuticals

This table shows Phathom Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -198 -202 -334
Consolidated Net Income / (Loss)		 -198 -202 -334
Net Income / (Loss) Continuing Operations		 -198 -202 -334
Total Pre-Tax Income 		-198 -202 -334
Total Operating Income		 -172 -167 -277
Total Gross Profit		 0.00 0.52 47
Total Revenue		 0.00 0.68 55
Operating Revenue		 0.00 0.68 55
Total Cost of Revenue		 0.00 0.17 7.97
Operating Cost of Revenue		 0.00 0.17 7.97
Total Operating Expenses		 172 168 325
Selling, General & Admin Expense		 101 118 291
Research & Development Expense		 71 50 34
Total Other Income / (Expense), net		 -25 -34 -57
Interest Expense		 27 42 72
Interest & Investment Income		 2.13 7.88 15
Other Income / (Expense), net		 -0.11 -0.19 -0.01
Basic Earnings per Share		 ($5.05) ($3.93) ($5.29)
Weighted Average Basic Shares Outstanding		 39.12M 51.29M 63.18M
Diluted Earnings per Share		 ($5.05) ($3.93) ($5.29)
Weighted Average Diluted Shares Outstanding		 39.12M 51.29M 63.18M
Weighted Average Basic & Diluted Shares Outstanding		 41.97M 58.48M 69.64M

Quarterly Income Statements for Phathom Pharmaceuticals

This table shows Phathom Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -51 -55 -38 -41 -43 -80 -83 -91 -86 -74
Consolidated Net Income / (Loss)		 -51 -55 -38 -41 -43 -80 -83 -91 -86 -74
Net Income / (Loss) Continuing Operations		 -51 -55 -38 -41 -43 -80 -83 -91 -86 -74
Total Pre-Tax Income 		-51 -55 -38 -41 -43 -80 -83 -91 -86 -74
Total Operating Income		 -43 -47 -30 -32 -36 -70 -70 -77 -71 -59
Total Gross Profit		 0.00 - 0.00 0.00 0.00 0.52 1.49 5.95 14 26
Total Revenue		 0.00 - 0.00 0.00 0.00 0.68 1.91 7.32 16 30
Operating Revenue		 - - 0.00 0.00 0.00 0.68 1.91 7.32 16 30
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 0.17 0.43 1.38 2.36 3.82
Operating Cost of Revenue		 - - 0.00 0.00 0.00 0.17 0.43 1.38 2.36 3.82
Total Operating Expenses		 43 47 30 32 36 70 71 83 85 85
Selling, General & Admin Expense		 24 31 19 19 23 57 62 76 76 77
Research & Development Expense		 19 16 11 13 12 13 9.43 7.38 8.69 8.58
Total Other Income / (Expense), net		 -8.56 -8.41 -7.74 -9.26 -7.58 -9.70 -13 -14 -15 -15
Interest Expense		 9.28 9.60 9.22 9.62 10 13 17 18 18 19
Interest & Investment Income		 0.73 1.29 1.46 0.35 2.72 3.35 4.31 3.62 3.71 3.51
Other Income / (Expense), net		 -0.01 -0.09 0.02 0.00 -0.20 -0.01 -0.04 -0.01 -0.01 0.05
Basic Earnings per Share		 ($1.32) ($1.33) ($0.89) ($0.84) ($0.76) ($1.44) ($1.42) ($1.56) ($1.32) ($0.99)
Weighted Average Basic Shares Outstanding		 38.82M 39.12M 42.35M 48.50M 56.78M 51.29M 58.37M 58.56M 64.63M 63.18M
Diluted Earnings per Share		 ($1.32) ($1.33) ($0.89) ($0.84) ($0.76) ($1.44) ($1.42) ($1.56) ($1.32) ($0.99)
Weighted Average Diluted Shares Outstanding		 38.82M 39.12M 42.35M 48.50M 56.78M 51.29M 58.37M 58.56M 64.63M 63.18M
Weighted Average Basic & Diluted Shares Outstanding		 41.62M 41.97M 43.61M 56.80M 57.25M 58.48M 58.54M 59.59M 68.38M 69.64M

Annual Cash Flow Statements for Phathom Pharmaceuticals

This table details how cash moves in and out of Phathom Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -28 228 -84
Net Cash From Operating Activities		 -147 -138 -267
Net Cash From Continuing Operating Activities		 -147 -138 -267
Net Income / (Loss) Continuing Operations		 -198 -202 -334
Consolidated Net Income / (Loss)		 -198 -202 -334
Depreciation Expense		 0.62 0.58 0.80
Amortization Expense		 2.11 1.88 2.19
Non-Cash Adjustments To Reconcile Net Income		 41 75 80
Changes in Operating Assets and Liabilities, net		 7.08 -14 -15
Net Cash From Investing Activities		 -1.04 -1.63 -0.14
Net Cash From Continuing Investing Activities		 -1.04 -1.63 -0.14
Purchase of Property, Plant & Equipment		 -1.04 -1.63 -0.14
Net Cash From Financing Activities		 120 368 183
Net Cash From Continuing Financing Activities		 120 368 183
Issuance of Debt		 0.00 181 181
Issuance of Common Equity		 25 14 0.00
Other Financing Activities, net		 95 173 1.60
Cash Interest Paid		 7.03 11 17

Quarterly Cash Flow Statements for Phathom Pharmaceuticals

This table details how cash moves in and out of Phathom Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 -11 -41 -26 119 -33 168 -59 -46 58 -37
Net Cash From Operating Activities		 -35 -41 -40 -22 -32 -44 -69 -71 -64 -63
Net Cash From Continuing Operating Activities		 -35 -41 -40 -22 -32 -44 -69 -71 -64 -63
Net Income / (Loss) Continuing Operations		 -51 -55 -38 -41 -43 -80 -83 -91 -86 -74
Consolidated Net Income / (Loss)		 -51 -55 -38 -41 -43 -80 -83 -91 -86 -74
Depreciation Expense		 0.18 0.17 0.15 0.12 0.12 0.19 0.21 0.20 0.19 0.19
Amortization Expense		 0.56 0.50 0.50 0.27 0.54 0.57 0.47 0.50 0.59 0.63
Non-Cash Adjustments To Reconcile Net Income		 12 13 14 14 14 34 20 21 20 19
Changes in Operating Assets and Liabilities, net		 2.91 -0.07 -16 4.38 -3.12 1.29 -7.07 -0.67 1.34 -9.08
Net Cash From Investing Activities		 -0.13 -0.41 -0.21 -0.01 -0.94 -0.48 -0.04 -0.05 -0.04 -0.01
Net Cash From Continuing Investing Activities		 -0.13 -0.41 -0.21 -0.01 -0.94 -0.48 -0.04 -0.05 -0.04 -0.01
Purchase of Property, Plant & Equipment		 -0.13 -0.41 -0.21 -0.01 -0.94 -0.48 -0.04 -0.05 -0.04 -0.01
Net Cash From Financing Activities		 25 - 14 142 0.01 212 9.90 25 122 26
Net Cash From Continuing Financing Activities		 25 - 14 142 0.01 212 9.90 25 122 26
Issuance of Debt		 - - 0.00 141 - 39 9.90 25 122 25
Other Financing Activities, net		 - - - - 0.01 173 - - 0.28 1.30
Cash Interest Paid		 2.02 2.10 2.55 2.76 2.91 2.91 3.74 4.08 4.66 4.82

Annual Balance Sheets for Phathom Pharmaceuticals

This table presents Phathom Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Total Assets		 165 414 378
Total Current Assets		 161 397 360
Cash & Equivalents		 155 381 297
Restricted Cash		 0.51 2.86 2.86
Accounts Receivable		 0.00 1.64 39
Inventories, net		 0.00 1.21 3.21
Prepaid Expenses		 5.13 13 21
Plant, Property, & Equipment, net		 1.21 2.15 1.48
Total Noncurrent Assets		 2.59 11 14
Other Noncurrent Operating Assets		 2.59 11 14
Total Liabilities & Shareholders' Equity		 165 414 378
Total Liabilities		 240 487 632
Total Current Liabilities		 26 39 86
Accounts Payable		 10.00 13 11
Accrued Expenses		 15 17 53
Current Deferred Revenue		 0.00 7.11 20
Other Current Liabilities		 0.71 0.73 0.50
Other Current Nonoperating Liabilities		 0.85 1.15 1.71
Total Noncurrent Liabilities		 213 448 546
Long-Term Debt		 95 138 201
Noncurrent Deferred Revenue		 110 300 333
Other Noncurrent Operating Liabilities		 8.60 10 12
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -75 -73 -254
Total Preferred & Common Equity		 -75 -73 -254
Preferred Stock		 0.00 0.00 0.00
Total Common Equity		 -75 -73 -254
Common Stock		 652 856 1,009
Retained Earnings		 -727 -929 -1,263
Treasury Stock		 0.00 0.00 0.00

Quarterly Balance Sheets for Phathom Pharmaceuticals

This table presents Phathom Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 202 144 265 237 356 319 387
Total Current Assets		 198 140 258 227 340 305 374
Cash & Equivalents		 197 130 249 214 322 276 335
Restricted Cash		 - - - - 2.87 2.86 2.86
Accounts Receivable		 - - - - 3.88 11 21
Inventories, net		 - - 0.11 0.11 1.46 2.18 3.11
Prepaid Expenses		 0.98 10 8.76 13 13 15 15
Plant, Property, & Equipment, net		 0.83 1.28 1.16 1.98 1.96 1.81 1.66
Total Noncurrent Assets		 3.29 2.89 6.16 8.29 11 9.91 8.71
Other Noncurrent Operating Assets		 3.29 2.89 6.16 8.29 11 9.91 8.71
Total Liabilities & Shareholders' Equity		 202 144 265 237 356 319 387
Total Liabilities		 228 234 247 255 505 553 574
Total Current Liabilities		 23 14 22 24 43 47 65
Accounts Payable		 7.14 4.81 4.17 5.79 8.40 7.66 7.13
Accrued Expenses		 13 8.02 15 14 17 27 36
Current Deferred Revenue		 - - 0.28 2.39 16 9.91 20
Other Current Liabilities		 1.63 0.71 0.72 0.72 0.73 0.72 0.68
Other Current Nonoperating Liabilities		 0.69 0.91 0.93 0.96 1.31 1.43 1.52
Total Noncurrent Liabilities		 205 220 226 231 462 506 509
Long-Term Debt		 94 97 98 99 149 174 176
Noncurrent Deferred Revenue		 - - 120 123 303 321 322
Other Noncurrent Operating Liabilities		 112 123 8.29 8.13 9.99 11 11
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -26 -90 18 -18 -149 -234 -187
Total Preferred & Common Equity		 -26 -90 18 -18 -149 -234 -187
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -26 -90 18 -18 -149 -234 -187
Common Stock		 646 675 823 831 863 869 1,001
Retained Earnings		 -672 -765 -806 -849 -1,012 -1,103 -1,189
Treasury Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Annual Metrics and Ratios for Phathom Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Phathom Pharmaceuticals' official financial filings.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - -
Revenue Growth		 0.00% 0.00% 8,001.47%
EBITDA Growth		 -27.67% 2.81% -66.31%
EBIT Growth		 -25.82% 2.93% -65.66%
NOPAT Growth		 -27.66% 2.97% -65.84%
Net Income Growth		 -37.42% -1.96% -65.84%
EPS Growth		 -29.82% 22.18% -34.61%
Operating Cash Flow Growth		 1.30% 6.11% -93.90%
Free Cash Flow Firm Growth		 94.08% 1,037.16% -343.76%
Invested Capital Growth		 -542.26% -136.30% -10.24%
Revenue Q/Q Growth		 0.00% 0.00% 110.32%
EBITDA Q/Q Growth		 -8.74% -16.25% 3.72%
EBIT Q/Q Growth		 -8.61% -16.04% 3.65%
NOPAT Q/Q Growth		 -8.56% -16.13% 3.63%
Net Income Q/Q Growth		 -10.77% -13.85% 1.51%
EPS Q/Q Growth		 -8.14% -2.88% 7.84%
Operating Cash Flow Q/Q Growth		 0.15% -2.04% -7.96%
Free Cash Flow Firm Q/Q Growth		 53.16% 167.46% -1,205.84%
Invested Capital Q/Q Growth		 -4.58% -142.34% -0.92%
Profitability Metrics		 - - -
Gross Margin		 0.00% 75.51% 85.57%
EBITDA Margin		 0.00% -24,200.59% -496.79%
Operating Margin		 0.00% -24,532.55% -502.18%
EBIT Margin		 0.00% -24,560.12% -502.20%
Profit (Net Income) Margin		 0.00% -29,558.94% -605.09%
Tax Burden Percent		 100.00% 100.00% 100.00%
Interest Burden Percent		 114.59% 120.35% 120.49%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00%
Return on Equity (ROE)		 14,877.58% 273.21% 204.89%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -57.89% -70.06%
Return on Assets (ROA)		 0.00% -69.68% -84.41%
Return on Common Equity (ROCE)		 14,877.58% 273.21% 204.89%
Return on Equity Simple (ROE_SIMPLE)		 264.29% 277.07% 131.84%
Net Operating Profit after Tax (NOPAT)		 -121 -117 -194
NOPAT Margin		 0.00% -17,172.79% -351.53%
Net Nonoperating Expense Percent (NNEP)		 -100.75% -55.39% -81.86%
Return On Investment Capital (ROIC_SIMPLE)		 - -179.95% 372.29%
Cost of Revenue to Revenue		 0.00% 24.49% 14.43%
SG&A Expenses to Revenue		 0.00% 17,291.50% 526.07%
R&D to Revenue		 0.00% 7,316.57% 61.68%
Operating Expenses to Revenue		 0.00% 24,608.06% 587.75%
Earnings before Interest and Taxes (EBIT)		 -173 -168 -277
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -170 -165 -274
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 766.45 10.05
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 405.13 8.26
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 4.17 0.00
Leverage & Solvency		 - - -
Debt to Equity		 -1.27 -1.89 -0.79
Long-Term Debt to Equity		 -1.27 -1.89 -0.79
Financial Leverage		 57.52 2.07 1.05
Leverage Ratio		 -133.27 -3.92 -2.43
Compound Leverage Factor		 -152.72 -4.72 -2.92
Debt to Total Capital		 465.84% 211.79% -386.06%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 465.84% 211.79% -386.06%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -365.84% -111.79% 486.06%
Debt to EBITDA		 -0.56 -0.84 -0.73
Net Debt to EBITDA		 0.36 1.49 0.36
Long-Term Debt to EBITDA		 -0.56 -0.84 -0.73
Debt to NOPAT		 -0.79 -1.18 -1.04
Net Debt to NOPAT		 0.50 2.10 0.51
Long-Term Debt to NOPAT		 -0.79 -1.18 -1.04
Altman Z-Score		 -7.48 -2.79 -5.55
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 6.12 10.25 4.20
Quick Ratio		 5.92 9.88 3.92
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -7.08 66 -162
Operating Cash Flow to CapEx		 -14,075.89% -8,419.83% -197,607.41%
Free Cash Flow to Firm to Interest Expense		 -0.26 1.58 -2.25
Operating Cash Flow to Interest Expense		 -5.37 -3.28 -3.70
Operating Cash Flow Less CapEx to Interest Expense		 -5.40 -3.32 -3.71
Efficiency Ratios		 - - -
Asset Turnover		 0.00 0.00 0.14
Accounts Receivable Turnover		 0.00 0.00 2.73
Inventory Turnover		 0.00 0.00 3.61
Fixed Asset Turnover		 0.00 0.41 30.51
Accounts Payable Turnover		 0.00 0.01 0.69
Days Sales Outstanding (DSO)		 0.00 0.00 133.56
Days Inventory Outstanding (DIO)		 0.00 0.00 101.08
Days Payable Outstanding (DPO)		 0.00 24,695.42 528.94
Cash Conversion Cycle (CCC)		 0.00 -24,695.42 -294.30
Capital & Investment Metrics		 - - -
Invested Capital		 -135 -318 -351
Invested Capital Turnover		 0.00 0.00 -0.17
Increase / (Decrease) in Invested Capital		 -114 -183 -33
Enterprise Value (EV)		 406 276 457
Market Capitalization		 467 523 555
Book Value per Share		 ($1.80) ($1.27) ($3.71)
Tangible Book Value per Share		 ($1.80) ($1.27) ($3.71)
Total Capital		 20 65 -52
Total Debt		 95 138 201
Total Long-Term Debt		 95 138 201
Net Debt		 -61 -246 -99
Capital Expenditures (CapEx)		 1.04 1.63 0.14
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -22 -26 -26
Debt-free Net Working Capital (DFNWC)		 134 359 274
Net Working Capital (NWC)		 134 359 274
Net Nonoperating Expense (NNE)		 77 84 140
Net Nonoperating Obligations (NNO)		 -60 -245 -97
Total Depreciation and Amortization (D&A)		 2.73 2.45 2.99
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -3,754.40% -46.55%
Debt-free Net Working Capital to Revenue		 0.00% 52,588.12% 496.64%
Net Working Capital to Revenue		 0.00% 52,588.12% 496.64%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 ($5.05) $0.00 ($5.29)
Adjusted Weighted Average Basic Shares Outstanding		 39.12M 0.00 63.18M
Adjusted Diluted Earnings per Share		 ($5.05) $0.00 ($5.29)
Adjusted Weighted Average Diluted Shares Outstanding		 39.12M 0.00 63.18M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 41.97M 0.00 69.64M
Normalized Net Operating Profit after Tax (NOPAT)		 -121 -117 -194
Normalized NOPAT Margin		 0.00% -17,172.79% -351.53%
Pre Tax Income Margin		 0.00% -29,558.94% -605.09%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 -6.32 -3.99 -3.85
NOPAT to Interest Expense		 -4.42 -2.79 -2.70
EBIT Less CapEx to Interest Expense		 -6.36 -4.03 -3.86
NOPAT Less CapEx to Interest Expense		 -4.46 -2.83 -2.70
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Phathom Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Phathom Pharmaceuticals' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4,249.56%
EBITDA Growth		 -27.97% -42.12% 21.07% 29.95% 15.81% -50.08% -135.62% -144.74% -98.97% 15.32%
EBIT Growth		 -20.90% -41.37% 20.72% 30.13% 15.71% -49.55% -132.88% -143.88% -97.47% 15.05%
NOPAT Growth		 -28.34% -41.17% 20.65% 30.12% 16.15% -49.81% -132.58% -143.84% -98.54% 14.97%
Net Income Growth		 -39.36% -53.65% 7.01% 19.55% 15.36% -44.55% -119.10% -123.23% -97.90% 6.43%
EPS Growth		 -34.69% -40.00% 16.82% 36.84% 42.42% -8.27% -59.55% -85.71% -73.68% 31.25%
Operating Cash Flow Growth		 -20.47% 0.54% 11.37% 13.67% 8.86% -6.72% -73.99% -218.56% -99.20% -44.89%
Free Cash Flow Firm Growth		 586.46% 268.36% 310.67% -118.43% -133.82% 66.12% 64.18% 1,458.93% 842.99% -106.72%
Invested Capital Growth		 -294.56% -542.26% -1,331.65% -9.16% -1.97% -136.30% -164.50% -154.37% -164.72% -10.24%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 180.35% 283.05% 123.27% 81.41%
EBITDA Q/Q Growth		 6.45% -10.21% 36.15% -6.42% -12.43% -96.45% -0.25% -10.53% 8.60% 16.39%
EBIT Q/Q Growth		 6.23% -9.85% 35.68% -5.46% -13.12% -94.92% -0.15% -10.44% 8.41% 16.15%
NOPAT Q/Q Growth		 6.25% -9.67% 35.52% -5.40% -12.49% -95.95% -0.11% -10.50% 8.41% 16.07%
Net Income Q/Q Growth		 -0.34% -7.74% 31.31% -8.33% -5.56% -84.01% -4.12% -10.37% 6.42% 13.00%
EPS Q/Q Growth		 0.75% -0.76% 33.08% 5.62% 9.52% -89.47% 1.39% -9.86% 15.38% 25.00%
Operating Cash Flow Q/Q Growth		 -36.16% -17.21% 3.34% 44.04% -43.76% -37.23% -57.59% -2.46% 10.11% 0.18%
Free Cash Flow Firm Q/Q Growth		 10.35% 22.13% 14.38% -111.95% -102.54% 699.92% 13.05% -1.07% 10.74% -105.42%
Invested Capital Q/Q Growth		 -6.02% -4.58% 9.19% -8.42% 0.97% -142.34% -1.65% -4.27% -3.06% -0.92%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 75.51% 77.72% 81.21% 85.59% 87.14%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -10,137.54% -3,624.95% -1,046.00% -428.23% -197.36%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -10,245.60% -3,658.68% -1,055.43% -432.95% -200.30%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -10,247.65% -3,660.93% -1,055.52% -433.00% -200.13%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -11,667.16% -4,333.26% -1,248.58% -523.34% -250.98%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 120.10% 117.79% 125.81% 129.24% 120.60% 113.85% 118.37% 118.29% 120.86% 125.41%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -463.29% 14,877.58% 747.21% -3,489.00% 801.29% 273.21% 206.65% 274.81% 331.35% 204.89%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -24.16% -37.95% -35.83% -36.46% -27.92%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -27.50% -44.92% -42.38% -44.06% -35.01%
Return on Common Equity (ROCE)		 -463.29% 14,877.58% 747.21% -3,489.00% 801.29% 273.21% 206.65% 274.81% 331.35% 204.89%
Return on Equity Simple (ROE_SIMPLE)		 675.56% 0.00% 216.06% -1,050.66% 996.28% 0.00% 166.08% 127.06% 181.41% 0.00%
Net Operating Profit after Tax (NOPAT)		 -30 -33 -21 -22 -25 -49 -49 -54 -50 -42
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -7,171.92% -2,561.08% -738.80% -303.07% -140.21%
Net Nonoperating Expense Percent (NNEP)		 -17.89% -29.30% -42.65% -14.20% -16.95% -20.10% -32.77% -29.47% -26.32% -19.20%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -75.15% - - - 79.72%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 24.49% 22.28% 18.79% 14.41% 12.86%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 8,357.33% 3,243.20% 1,035.94% 465.38% 258.51%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 1,963.78% 493.20% 100.71% 53.16% 28.93%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 10,321.11% 3,736.40% 1,136.65% 518.54% 287.44%
Earnings before Interest and Taxes (EBIT)		 -43 -47 -30 -32 -36 -70 -70 -77 -71 -59
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -42 -46 -29 -31 -35 -69 -69 -77 -70 -59
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 35.49 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 35.49 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 766.45 239.41 60.73 41.01 10.05
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 405.13 171.53 50.18 34.86 8.26
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 4.17 7.94 18.02 62.63 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 -3.55 -1.27 -1.07 5.56 -5.58 -1.89 -1.00 -0.75 -0.94 -0.79
Long-Term Debt to Equity		 -3.55 -1.27 -1.07 5.56 -5.58 -1.89 -1.00 -0.75 -0.94 -0.79
Financial Leverage		 -3.09 57.52 1.51 -24.95 4.88 2.07 0.87 1.17 1.34 1.05
Leverage Ratio		 5.58 -133.27 -5.62 45.15 -9.93 -3.92 -2.10 -2.70 -3.05 -2.43
Compound Leverage Factor		 6.71 -156.99 -7.07 58.34 -11.98 -4.46 -2.48 -3.20 -3.68 -3.04
Debt to Total Capital		 139.17% 465.84% 1,499.89% 84.75% 121.81% 211.79% 28,658.27% -293.61% -1,543.78% -386.06%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 139.17% 465.84% 1,499.89% 84.75% 121.81% 211.79% 28,658.27% -293.61% -1,543.78% -386.06%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -39.17% -365.84% -1,399.89% 15.25% -21.81% -111.79% -28,558.27% 393.61% 1,643.78% 486.06%
Debt to EBITDA		 -0.60 -0.56 -0.60 -0.66 -0.70 -0.84 -0.73 -0.70 -0.62 -0.73
Net Debt to EBITDA		 0.66 0.36 0.20 1.02 0.81 1.49 0.86 0.42 0.57 0.36
Long-Term Debt to EBITDA		 -0.60 -0.56 -0.60 -0.66 -0.70 -0.84 -0.73 -0.70 -0.62 -0.73
Debt to NOPAT		 -0.84 -0.79 -0.84 -0.93 -0.98 -1.18 -1.03 -0.99 -0.87 -1.04
Net Debt to NOPAT		 0.93 0.50 0.29 1.43 1.13 2.10 1.21 0.59 0.80 0.51
Long-Term Debt to NOPAT		 -0.84 -0.79 -0.84 -0.93 -0.98 -1.18 -1.03 -0.99 -0.87 -1.04
Altman Z-Score		 -3.17 -4.97 -6.31 -2.07 -3.10 -2.01 -2.88 -3.98 -2.75 -3.65
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 8.65 6.12 9.68 11.96 9.46 10.25 7.83 6.48 5.73 4.20
Quick Ratio		 8.60 5.92 8.97 11.55 8.91 9.88 7.50 6.11 5.45 3.92
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 66 81 93 -11 -22 135 152 150 167 -9.03
Operating Cash Flow to CapEx		 -26,131.34% -9,961.41% -18,536.92% -370,000.00% -3,398.72% -9,220.42% -172,550.00% -153,741.30% -144,484.09% -1,269,120.00%
Free Cash Flow to Firm to Interest Expense		 7.15 8.43 10.05 -1.15 -2.22 10.33 8.86 8.47 9.01 -0.49
Operating Cash Flow to Interest Expense		 -3.77 -4.27 -4.30 -2.31 -3.16 -3.36 -4.02 -3.98 -3.44 -3.41
Operating Cash Flow Less CapEx to Interest Expense		 -3.79 -4.32 -4.33 -2.31 -3.25 -3.40 -4.02 -3.98 -3.44 -3.41
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.03 0.08 0.14
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.73
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.72 2.68 3.61
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.41 1.60 6.68 14.47 30.51
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.01 0.09 0.33 0.67 0.69
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 133.56
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 212.07 135.96 101.08
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 24,695.42 4,064.86 1,096.48 545.47 528.94
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 -24,695.42 -4,064.86 -884.42 -409.52 -294.30
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -129 -135 -122 -133 -131 -318 -323 -337 -347 -351
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 -0.01 -0.04 -0.11 -0.17
Increase / (Decrease) in Invested Capital		 -96 -114 -114 -11 -2.54 -183 -201 -205 -216 -33
Enterprise Value (EV)		 331 406 267 474 475 276 445 498 916 457
Market Capitalization		 434 467 300 625 589 523 621 602 1,077 555
Book Value per Share		 ($0.67) ($1.80) ($2.15) $0.40 ($0.31) ($1.27) ($2.54) ($4.00) ($3.14) ($3.71)
Tangible Book Value per Share		 ($0.67) ($1.80) ($2.15) $0.40 ($0.31) ($1.27) ($2.54) ($4.00) ($3.14) ($3.71)
Total Capital		 67 20 6.44 115 81 65 0.52 -59 -11 -52
Total Debt		 94 95 97 98 99 138 149 174 176 201
Total Long-Term Debt		 94 95 97 98 99 138 149 174 176 201
Net Debt		 -103 -61 -33 -151 -114 -246 -176 -105 -162 -99
Capital Expenditures (CapEx)		 0.13 0.41 0.21 0.01 0.94 0.48 0.04 0.05 0.04 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -22 -22 -4.17 -13 -11 -26 -28 -21 -29 -26
Debt-free Net Working Capital (DFNWC)		 175 134 125 236 203 359 297 258 309 274
Net Working Capital (NWC)		 175 134 125 236 203 359 297 258 309 274
Net Nonoperating Expense (NNE)		 21 22 17 19 18 31 34 37 36 33
Net Nonoperating Obligations (NNO)		 -102 -60 -32 -150 -113 -245 -175 -103 -160 -97
Total Depreciation and Amortization (D&A)		 0.74 0.67 0.64 0.40 0.66 0.75 0.69 0.70 0.78 0.82
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% -3,754.40% -1,088.70% -214.97% -110.42% -46.55%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 52,588.12% 11,443.91% 2,599.10% 1,174.47% 496.64%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 52,588.12% 11,443.91% 2,599.10% 1,174.47% 496.64%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($1.33) ($0.89) ($0.84) ($0.76) ($1.44) ($1.42) ($1.56) ($1.32) ($0.99)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 39.12M 42.35M 48.50M 56.78M 51.29M 58.37M 58.56M 64.63M 63.18M
Adjusted Diluted Earnings per Share		 $0.00 ($1.33) ($0.89) ($0.84) ($0.76) ($1.44) ($1.42) ($1.56) ($1.32) ($0.99)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 39.12M 42.35M 48.50M 56.78M 51.29M 58.37M 58.56M 64.63M 63.18M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 41.97M 43.61M 56.80M 57.25M 58.48M 58.54M 59.59M 68.38M 69.64M
Normalized Net Operating Profit after Tax (NOPAT)		 -30 -33 -21 -22 -25 -49 -49 -54 -50 -42
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -7,171.92% -2,561.08% -738.80% -303.07% -140.21%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -11,667.16% -4,333.26% -1,248.58% -523.34% -250.98%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -4.59 -4.87 -3.26 -3.30 -3.55 -5.36 -4.08 -4.35 -3.83 -3.19
NOPAT to Interest Expense		 -3.21 -3.40 -2.28 -2.31 -2.47 -3.75 -2.85 -3.05 -2.68 -2.24
EBIT Less CapEx to Interest Expense		 -4.60 -4.91 -3.28 -3.30 -3.64 -5.40 -4.08 -4.35 -3.83 -3.19
NOPAT Less CapEx to Interest Expense		 -3.22 -3.44 -2.31 -2.31 -2.56 -3.79 -2.85 -3.05 -2.68 -2.24
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Phathom Pharmaceuticals' Financials

When does Phathom Pharmaceuticals's fiscal year end?

According to the most recent income statement we have on file, Phathom Pharmaceuticals' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Phathom Pharmaceuticals' net income changed over the last 2 years?

Phathom Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$334.33 million in 2024, rising from -$197.72 million in 2022. The previous period was -$201.59 million in 2023. Find out what analysts predict for Phathom Pharmaceuticals in the coming months.

What is Phathom Pharmaceuticals's operating income?
Phathom Pharmaceuticals's total operating income in 2024 was -$277.47 million, based on the following breakdown:
  • Total Gross Profit: $47.28 million
  • Total Operating Expenses: $324.75 million
How has Phathom Pharmaceuticals revenue changed over the last 2 years?

Over the last 2 years, Phathom Pharmaceuticals' total revenue changed from $0.00 in 2022 to $55.25 million in 2024, a change of 5,525,200,000.0%.

How much debt does Phathom Pharmaceuticals have?

Phathom Pharmaceuticals' total liabilities were at $631.90 million at the end of 2024, a 29.9% increase from 2023, and a 163.7% increase since 2022.

How much cash does Phathom Pharmaceuticals have?

In the past 2 years, Phathom Pharmaceuticals' cash and equivalents has ranged from $155.39 million in 2022 to $381.39 million in 2023, and is currently $297.26 million as of their latest financial filing in 2024.

How has Phathom Pharmaceuticals' book value per share changed over the last 2 years?

Over the last 2 years, Phathom Pharmaceuticals' book value per share changed from -1.80 in 2022 to -3.71 in 2024, a change of 106.3%.


Related Companies

This page (NASDAQ:PHAT) was last updated on 5/6/2025 by MarketBeat.com Staff
From Our Partners
Elon’s Terrifying Warning Forces Trump To Take Action
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...
American Hartford Gold | Sponsored
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...
Porter & Company | Sponsored
Shocking AI play that’s beats Nvidia by a country mile
You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...
Timothy Sykes | Sponsored
Altucher: Turn $900 into $108,000 in just 12 months?
We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.
Paradigm Press | Sponsored
Most traders are panicking. We’re cashing in
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....
Crypto Swap Profits | Sponsored
Trump’s Bitcoin Reserve is No Accident…
Crypto policy is changing fast… Smart investors are positioning themselves to benefit. And it's all happeni...
Crypto 101 Media | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...
Brownstone Research | Sponsored